EFTA00351821.pdf

From: To: Jeffrey Epstein Subject: Fwd: Fwd: Investment Opportunities-David Carter Date: Fri, 06 Mar 2015 15:42:07 +0000 Attachments: DaCart_Presentation Mar 2 2015.pptx Begin forwarded message: From: "David Carter" < Subject: FW: Investment Opportunities Date: March 6, 2015 at 10:28:30 AM EST To: From: David Carter [madto: Sent: Thursday, March 05, 2015 11:09 AM To: ben carter Subject: Investment Opportunities Dear Lesley, Here is my email for Jeffery. Thanks, David Dear Jeffery, James Meiskin suggested you might have an interest in what I am doing. Since you offered to look at what I am up to, I have attached the full story. It is essentially the presentation I made in Moscow several years ago. I am now working with Russian Venture on the first, of what we both think will be a series of investments. As you can imagine, "the full story" is best told with a narrator, but maybe you can get an idea of what I am doing by flipping through the slides. Hopefully, you will find something of enough interest that we might arrange a face to face meeting. I also thought you might want me to get to the point. I have no idea what your investment interests are, but some of the things I have read about you suggest that you would like to do good with your money, as well as doing well with your investments. This is just an impression, but if my impression is correct, I think I have some interesting things for you to consider. I will highlight the first three investment opportunities: MAJI Therapeutics: MAJI is focused on solving the major unmet medical need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MAJI in its Series A Round. I need to find the matching approximate $3.5M. I have a commitment for $1.5M, so I am looking for the final $2.0M piece to close the round in "early summer". I consider MAJI to be a rock solid investment, and an investment with a good chance to generate a 12X return in 4.5 years. Prediction Biosciences: Prediction has developed a diagnostic that accurately predicts (in a timely fashion) which stroke victims are safe to receive t-PA. A significant percent (30%-50%) of stroke victims have severe EFTA00351821 adverse reactions to t-PA, and knowing (in a timely fashion) which patients will respond well, and which will respond badly, would be a major advance in the treatment of stroke patients. (6%-11% of these "adverse responses" will be fatal.) Prediction is well along in its development. They just need about $1.5M to get into the clinic, and generate the data for product approval. With the clinical data in hand the balance of Prediction's financing should be relatively easy. OvationBio: OvationBio is super early. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the biggest medical problems in the world—hospital based infections, i.e. MRSA. In addition, OvationBio' s technology could produce human enzymes, in modified chickens, on a super cost effective basis. OvationBio needs to do proof of concept studies, and develop its intellectual property, before it starts to raise real money. OvationBio needs $1.5M to complete this early work. In olden days this would be something the NIH would fund, but there is no more real NIH money, so I am looking for private investors with a "civic minded interest". (The Russians Love OvationBio, but we need to show them "proof of concept", before they can/will invest.) ConcentRx: I like ConcentRx. It is personalized cancer therapy. We will only beat cancer when we learn to treat it individually, and one patient at a time. I am pretty sue I have the money for this one, but depending on your interest we can discuss it. So, for your consideration, you could pick a project that you liked, and dedicate a $1.5M ($2.0M in the case of MAJI) investment toward it. If you liked all three projects, you could invest $5.0M, and take the portfolio approach. As I have confessed, I am shooting in the dark here, but James has assured me you have at least the potential to find an idea you like among this things I am doing. Thank you for your consideration. Kind regards, David David W. Carter President—DaCart Capital LLC 1485 Main St Suite 301 St Helena, CA 94574 (510) 205-3175 Cell (707) 967-0556 Fax EFTA00351822